BriaCell Therapeutics Corp 6-K, filed Nov 12, 2021
BriaCell Therapeutics Corp. (BCTX)
About this 6-K
BriaCell Therapeutics Corp filed this 6-K on November 12, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2021
Commission File Number: 001-40101
BRIACELL THERAPEUTICS CORP.
(Translation of registrant’s name into English)
Suite 300 – 235 15th Street
West Vancouver, BC V7T 2X1
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☐ Form 40-F ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Exhibit Number |
Description | |
| 99.1 | Press Release dated November 12, 2021 issued by BriaCell Therapeutics Corp. | |
| 99.2 | Notice of Meeting |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BriaCell Therapeutics Corp. | ||
| Date: November 12, 2021 | By: | /s/ William V. Williams |
| Name: | William V. Williams | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences
BERKELEY, Calif. and VANCOUVER, British Columbia, November 12, 2021— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the following updates:
Pursuant to the securities buyback program announced Sept. 9, 2021, BriaCell has repurchased 202,425 common shares (the “Common Shares”) and 70,246 publicly traded BCTXW warrants (the “Listed Warrants”). As announced, BriaCell may purchase through the facilities of the TSX Venture Exchange (“TSXV”) or the Nasdaq Capital Market (“Nasdaq”) or alternative exchanges (i) up to 1,341,515 Common Shares and (ii) up to 411,962 publicly traded BCTXW Listed Warrants in total, representing 10% of the 13,415,154 Common Shares and 10% of the 4,119,622 Listed Warrants comprising the “public float” as of September 8, 2021, over the next 12 months.
BriaCell is fully-capitalized to achieve its strategic clinical milestones. Because of this BriaCell’s Board of Directors believes the best use of a portion of its excess capital at this time is to buy back its own Common Shares and Listed Warrants for cancellation. As of July 31, 2021, BriaCell’s cash balance was US$57.3 million which provides the strength and flexibility to execute both the buyback program and BriaCell’s growth strategy to expand into previously-announced areas of cancer immunotherapy and/or advance its current breast cancer clinical trials.
Separately, the Company announces that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to present at the following virtual conferences:
| ● | Q4 Investor Summit: November 16 – 17, 2021 | |
| ○ | Dr. Williams will deliver his corporate presentation at 10:15 a.m. ET on November 16, 2021 | |
| ○ | Investors may register for the conference at: https://investorsummitgroup.com/ | |
| ○ | Investors may request one-on-one meetings with management | |
| ○ | A public webcast can be accessed via the following link: | |
| https://us06web.zoom.us/webinar/register/WN_qK33aeh9TOmLiCnC-GM91w | ||
| ● | The 2021 San Antonio Breast Cancer Symposium®: December 7 – 10, 2021 | ||
| ○ | BriaCell’s lead product candidate, Bria-IMT™, will be featured during the following: | ||
| ● | Poster Session 2: 5:00 - 6:30 p.m. CT on Wednesday, December 8, 2021 | ||
| ● | Presentation Title: Overall Survival Following Treatment with a Modified Whole Tumor Cell Targeted Immunotherapy in Patients with Advanced Breast Cancer | ||
| ○ | The poster presentation will be accessible at a later date at: | ||
| https://briacell.com/novel-technology/scientific-publications/ | |||
| ● | MedInvest Oncology Conference: December 7 – 10, 2021 | |
| ○ | Dr. Williams will be speaking at the conference at 2:30 p.m. ET on December 7, 2021 | |
| ○ | Investors may register for the conference at: https://www.medinvestconferences.com/ | |
| ○ | Investors may request on-on-one meetings with management | |
| ● | Benzinga Global Small Cap Virtual Investor Conference: December 8 – 9, 2021 | |
| ○ | Dr. Williams will be speaking at the conference at 1:35 p.m. ET on December 9, 2021 | |
| ○ | Investors may register for the conference at: | |
| https://www.benzinga.com/events/small-cap/december-2021-global/ | ||
| ○ | Investors may request on-on-one meetings with management | |
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
Exhibit 99.2
 | |
| November 12, 2021 | 510 Burrard St, 3rd Floor |
Vancouver BC, V6C 3B9 www.computershare.com |
To: All Canadian Securities Regulatory Authorities
NASDAQ Exchange
Subject: BRIACELL THERAPEUTICS CORP.
Dear Sir/Madam:
We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer:
| Meeting Type : | Annual General and Special Meeting |
| Record Date for Notice of Meeting : | December 09, 2021 |
| Record Date for Voting (if applicable) : | December 09, 2021 |
| Beneficial Ownership Determination Date : | December 09, 2021 |
| Meeting Date : | January 18, 2022 |
| Meeting Location (if available) : | TBD |
| Issuer sending proxy related materials directly to NOBO: | Yes |
| Issuer paying for delivery to OBO: | No |
| Notice and Access (NAA) Requirements: | |
| NAA for Beneficial Holders | No |
| NAA for Registered Holders | No |
Voting Security Details:
| Description | CUSIP Number | ISIN | ||
| COMMON CLASS | 10778Y302 | CA10778Y3023 |
Sincerely,
Computershare
Agent for BRIACELL THERAPEUTICS CORP.